Health GAP and its partners on Wednesday released a report that “looks at the PEPFAR ‘transition’ in [South Africa] — moving from ‘directly supporting’ over one million people on ARV treatment in South Africa in early 2011 to a near complete withdrawal from support for ‘direct services.’ … The report finds that the political transition — toward increased South African ownership and innovative models of shared governance for U.S. funds — is yielding important benefits … [and] recommends an urgent course correction for PEPFAR South Africa — tracing patients and health workers while considering a more measured approach in the country,” according to press release. The report accompanies an article forthcoming in the Journal of Acquired Immune Deficiency Syndromes (1/15).